Monsenso ASOCSE:MONSO +4.57%29 3-Year ROIIC % is -9.34 as of Dec. 2025. GuruFocus rates OCSE:MONSO with a GF Score™ of 29/100 and a GF Value™ of kr0.15 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 619 Healthcare Providers & Services companies, Monsenso AS ranks worse than 68.98% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Monsenso AS's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -9.34%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Monsenso AS's 3-Year ROIIC % or its related term are showing as below:
OCSE:MONSO's 3-Year ROIIC % is ranked worse than 68.98% of 619
companies
in the Healthcare Providers & Services industry
Industry Median: 3.46
vs OCSE:MONSO: -9.34
Monsenso AS (OCSE:MONSO) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Monsenso AS 3-Year ROIIC % Related Terms
Monsenso AS 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Monsenso AS's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:MONSO vs VEEV, BTSG, TEM: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, Monsenso AS's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monsenso AS 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Monsenso AS's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Monsenso AS's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Monsenso AS (OCSE:MONSO) has a 3-Year ROIIC % of -9.34 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Monsenso AS and its competitors. According to the industry distribution chart, Monsenso AS ranks #427 out of 619 companies in the Healthcare Providers & Services industry, placing it in the top 69%.
Is Monsenso AS's 3-Year ROIIC % too high?
Monsenso AS's current 3-Year ROIIC % is -9.34. Based on the distribution chart, Monsenso AS ranks #427 out of 619 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Monsenso AS has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Monsenso AS's 3-Year ROIIC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Monsenso AS ranks #427 out of 619 companies for 3-Year ROIIC %. This places Monsenso AS in the lower half of its industry. The industry median 3-Year ROIIC % is 3.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.46, based on 619 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Monsenso AS and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monsenso AS's current 3-Year ROIIC % is -9.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monsenso AS stock overvalued right now?
Based on GuruFocus' analysis, Monsenso AS (OCSE:MONSO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.37 — trading 144% above its estimated fair value. The current 3-Year ROIIC % is -9.34. Monsenso AS's overall GF Score™ is 29/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Monsenso AS (OCSE:MONSO), the current 3-Year ROIIC % is -9.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monsenso AS (OCSE:MONSO) Overvalued in 2026?
Based on GuruFocus' analysis, Monsenso AS stock appears to be overvalued.
The current stock price of kr0.37 is trading 144% above its estimated GF Value™ of kr0.15.
GuruFocus considers Monsenso AS to be Significantly Overvalued.
Key valuation signals for OCSE:MONSO:
3-Year ROIIC %: -9.34
GF Value™: kr0.15 vs. price of kr0.37 (144% above fair value)
No single metric tells the full story. See the OCSE:MONSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monsenso AS is a mobile mental health company. It technology company offering a digital health solution used for decentralized trials, remote patient monitoring, and treatment support. The company's mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data, and the solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence, and behavioral data.
29GF Score
Get the complete analysis for OCSE:MONSO
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:MONSO has been successfully added to your 
